These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 24649313)

  • 1. Sorafenib in metastatic radioactive iodine-refractory differentiated thyroid cancer: A pilot study.
    Luo Y; Shi Y; Xing P; Wang L; Feng Y; Han X; He X
    Mol Clin Oncol; 2014 Jan; 2(1):87-92. PubMed ID: 24649313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer.
    Brose MS; Nutting CM; Sherman SI; Shong YK; Smit JW; Reike G; Chung J; Kalmus J; Kappeler C; Schlumberger M
    BMC Cancer; 2011 Aug; 11():349. PubMed ID: 21834960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
    Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K
    Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tertiary Care Experience of Sorafenib in the Treatment of Progressive Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Korean Multicenter Study.
    Kim M; Kim TH; Shin DY; Lim DJ; Kim EY; Kim WB; Chung JH; Shong YK; Kim BH; Kim WG;
    Thyroid; 2018 Mar; 28(3):340-348. PubMed ID: 29350109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Donafenib in Progressive Locally Advanced or Metastatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Results of a Randomized, Multicenter Phase II Trial.
    Lin YS; Yang H; Ding Y; Cheng YZ; Shi F; Tan J; Deng ZY; Chen ZD; Wang RF; Ji QH; Huang R; Li LF
    Thyroid; 2021 Apr; 31(4):607-615. PubMed ID: 32907500
    [No Abstract]   [Full Text] [Related]  

  • 6. Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET.
    Marotta V; Ramundo V; Camera L; Del Prete M; Fonti R; Esposito R; Palmieri G; Salvatore M; Vitale M; Colao A; Faggiano A
    Clin Endocrinol (Oxf); 2013 May; 78(5):760-7. PubMed ID: 23009688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenvatinib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Candidate Biomarkers Associated with Survival: A Multicenter Study in Korea.
    Song E; Kim M; Kim EY; Kim BH; Shin DY; Kang HC; Ahn BC; Kim WB; Shong YK; Jeon MJ; Lim DJ
    Thyroid; 2020 May; 30(5):732-738. PubMed ID: 31910091
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience.
    Cabanillas ME; Waguespack SG; Bronstein Y; Williams MD; Feng L; Hernandez M; Lopez A; Sherman SI; Busaidy NL
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2588-95. PubMed ID: 20392874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor doubling time predicts response to sorafenib in radioactive iodine-refractory differentiated thyroid cancer.
    Kim MJ; Kim SM; Lee EK; Hwangbo Y; Lee YJ; Cho SW; Park DJ; Lee Y; Park YJ
    Endocr J; 2019 Jul; 66(7):597-604. PubMed ID: 31006722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sorafenib and Sunitinib for the Treatment of Metastatic Thyroid Cancer of Follicular Origin: A 7-Year Single-Centre Experience.
    Sousa Santos F; Joana Santos R; Leite V
    Eur Thyroid J; 2019 Oct; 8(5):262-267. PubMed ID: 31768337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological Features Predict Outcomes in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Sorafenib: A Real-World Study.
    Cheng L; Fu H; Jin Y; Sa R; Chen L
    Oncologist; 2020 Apr; 25(4):e668-e678. PubMed ID: 31957916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sorafenib treatment of radioiodine-refractory advanced thyroid cancer in daily clinical practice: a cohort study from a single center.
    Gallo M; Michelon F; Castiglione A; Felicetti F; Viansone AA; Nervo A; Zichi C; Ciccone G; Piovesan A; Arvat E
    Endocrine; 2015 Aug; 49(3):726-34. PubMed ID: 25414068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy and safety in radioactive iodine refractory thyroid cancer patients treated with sorafenib.
    Ling Y; Xiong X; Luo J; Zou Q; Chen P; Pan L; Long M; Feng H; Ouyang W
    Front Endocrinol (Lausanne); 2023; 14():1200932. PubMed ID: 37534207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sorafenib: a review of its use in patients with radioactive iodine-refractory, metastatic differentiated thyroid carcinoma.
    Blair HA; Plosker GL
    Target Oncol; 2015 Mar; 10(1):171-8. PubMed ID: 25742918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of Tyrosine Kinase Inhibitors in Patients With Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea.
    Kim SY; Kim SM; Chang H; Kim BW; Lee YS; Chang HS; Park CS
    Front Endocrinol (Lausanne); 2019; 10():384. PubMed ID: 31244783
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy of sorafenib in advanced differentiated and medullary thyroid cancer: experience in a Turkish population.
    Benekli M; Yalcin S; Ozkan M; Elkiran ET; Sevinc A; Cabuk D; Coskun HS; Oksuzoglu B; Bayar B; Akbulat A; Ozet A
    Onco Targets Ther; 2015; 8():1-5. PubMed ID: 25548522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer.
    Worden F; Fassnacht M; Shi Y; Hadjieva T; Bonichon F; Gao M; Fugazzola L; Ando Y; Hasegawa Y; Park DJ; Shong YK; Smit JW; Chung J; Kappeler C; Meinhardt G; Schlumberger M; Brose MS
    Endocr Relat Cancer; 2015 Dec; 22(6):877-87. PubMed ID: 26370187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The experience of an Endocrinology Division on the use of tyrosine multikinase inhibitor therapy in patients with radioiodine-resistant differentiated thyroid cancer.
    Jerkovich F; García Falcone MG; Pitoia F
    Endocrine; 2019 Jun; 64(3):632-638. PubMed ID: 30820748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended Real-World Observation of Patients Treated with Sorafenib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Impact of Lenvatinib Salvage Treatment: A Korean Multicenter Study.
    Oh HS; Shin DY; Kim M; Park SY; Kim TH; Kim BH; Kim EY; Kim WB; Chung JH; Shong YK; Lim DJ; Kim WG
    Thyroid; 2019 Dec; 29(12):1804-1810. PubMed ID: 31592739
    [No Abstract]   [Full Text] [Related]  

  • 20. Sorafenib and radioiodine-refractory differentiated thyroid cancer (RR-DTC): a systematic review and meta-analysis.
    Feng G; Luo Y; Zhang Q; Zeng F; Xu J; Zhu J
    Endocrine; 2020 Apr; 68(1):56-63. PubMed ID: 31955344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.